Propanc Biopharma, Inc.

Latest News

Aug 18, 2026

Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP

Avance Clinical to Lead Preparatory Activities for Multi-Center Investigation Across Australia MELBOURNE, Australia, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the…

View All Press Releases

Aug 12, 2026

Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers

Aug 6, 2026

Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models

Aug 5, 2026

Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program
Latest Publication Evaluation of recombinant trypsinogen and chymotrypsinogen production in Komagataella phaffii through co-expression of HAC1 and PDI1 View All Publications
Impact of pancreatic proenzymes on pancreatic ductal adenocarcinoma associated fibroblasts
Blocking Tumor Support from Cancer-Associated Fibroblasts in Tumor Microenvironment
Trypsinogen and chymotrypsinogen: potent anti- tumor agents